Mometasona Furoato Kern Pharma (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometasona Furoato Kern Pharma, is a corticosteroid presented as a nasal spray for intranasal use. It reduces nasal inflammation and is used to treat allergic rhinitis and other nasal inflammatory conditions in adults and children.

GNH USA supplies Mometasona Furoato Kern Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometasone furoate nasal spray is indicated for conditions affecting the nasal passages where inflammation is a primary component.

Allergic rhinitis: reduces nasal congestion, itching, sneezing and rhinorrhea. Nasal polyps: decreases polyp size and improves nasal airflow after surgical removal. Non‑allergic rhinitis: alleviates nasal inflammation and associated symptoms.

Mometasone furoate nasal spray may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation. - Headache. - Epistaxis (nosebleeds). - Throat irritation or dryness. - Altered taste perception.

Serious or Rare Side Effects: - Nasal fungal infection (e.g., Candida). - Adrenal suppression with prolonged high‑dose use. - Severe or persistent nosebleeds. - Vision changes such as cataracts or glaucoma. - Anaphylactic or severe allergic reactions.

Before using Mometasone furoate nasal spray, consider the following precautions.

Pregnancy: consult a healthcare provider before use. Pediatric use: safety not established for children under 2 years of age. Concurrent nasal surgery: avoid using shortly before or after the procedure. Long‑term use: monitor for signs of adrenal suppression. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mometasone furoate nasal spray can interact with other medications; review the following.

Major Interactions (Avoid): - Systemic corticosteroids: increased risk of systemic glucocorticoid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise local drug exposure. - Immunosuppressants: potential additive immunosuppression.

Moderate Interactions (Monitor Closely): - Antihistamines: may increase nasal dryness. - Decongestant nasal sprays: concurrent use may heighten local irritation.